GENT — Gentian Diagnostics ASA Share Price
0.000.00%
Last trade - 00:00- NOK771.12m
- NOK696.42m
- NOK152.07m
- 61
- 11
- 91
- 54
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 24.69 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -19.85% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.97 | ||
| Price to Tang. Book | 4.66 | ||
| Price to Free Cashflow | 307.59 | ||
| Price to Sales | 5.07 | ||
| EV to EBITDA | 28.21 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.88% | ||
| Return on Equity | 26.59% | ||
| Operating Margin | 10.34% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | NOKm | 63.33 | 83.12 | 101.64 | 135.15 | 152.07 | 201 | 261 | 25.96% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | -38.06 | +43.26 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Gentian Diagnostics ASA is a Norway-based company within health care sector. The Company develops and manufactures in vitro diagnostic (IVD) products for the detection and quantification of specific markers for use on a wide range of clinical chemistry analysers. The Company’s product portfolio comprises turbidimetric fecal calprotectin immunoassay, which is to be run on clinical chemistry analysers: The Gentian Calprotectin Immunoassay, Cystatin C, NT-proBNP - Pre-launch, SARS-CoV-2 Ab Pre-Launch, Canine CRP and Beckman Coulter Customers. The Company is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 1st, 2001
- Public Since
- December 14th, 2016
- No. of Employees
- 63
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Oslo Stock Exchange
- Shares in Issue
- 15,422,350
- Address
- Bjornasveien 5, MOSS, 1596
- Web
- https://www.gentian.com/
- Phone
- Contact
- Njaal Kind
- Auditors
- BDO AS
Upcoming Events for GENT
Similar to GENT
Codelab Capital AS
Oslo Stock Exchange
ContextVision AB
Oslo Stock Exchange
INIFY Laboratories AB
Oslo Stock Exchange
Medistim ASA
Oslo Stock Exchange
Nordhealth AS
Oslo Stock Exchange
FAQ
What is the Gentian Diagnostics ASA share price?
As of Today at 20:48 UTC, shares in Gentian Diagnostics ASA are trading at NOK50.00. This share price information is delayed by 15 minutes.
How has the Gentian Diagnostics ASA share price performed this year?
Shares in Gentian Diagnostics ASA last closed at NOK50.00 and the price had moved by +31.65% over the past 365 days. In terms of relative price strength the Gentian Diagnostics ASA share price has outperformed the FTSE Global All Cap Index by +28.35% over the past year.
What are the analyst and broker recommendations for Gentian Diagnostics ASA?
The overall consensus recommendation for Gentian Diagnostics ASA is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Gentian Diagnostics ASA dividend yield?
The Gentian Diagnostics ASA dividend yield is 0.8% based on the trailing twelve month period.
Does Gentian Diagnostics ASA pay a dividend?
Last year, Gentian Diagnostics ASA paid a total dividend of NOK0.40, and it currently has a trailing dividend yield of 0.8%.Looking ahead, shares in Gentian Diagnostics ASA are due to go ex-dividend on 2025-05-07 and the next dividend pay date is 2025-05-16.
When does Gentian Diagnostics ASA next pay dividends?
Gentian Diagnostics ASA are due to go ex-dividend on 2025-05-07 and the next dividend pay date is 2025-05-16. The historic dividend yield on Gentian Diagnostics ASA shares is currently 0.8%.
How do I buy Gentian Diagnostics ASA shares?
To buy shares in Gentian Diagnostics ASA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Gentian Diagnostics ASA?
As of the previous close price of NOK50.00, shares in Gentian Diagnostics ASA had a market capitalisation of NOK771.12m.
Where are Gentian Diagnostics ASA shares listed?
Here are the trading details for Gentian Diagnostics ASA:
- Country of listing: Norway
- Exchange: OSL
- Ticker Symbol: GENT
What kind of share is Gentian Diagnostics ASA?
Based on an overall assessment of its quality, value and momentum Gentian Diagnostics ASA is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Gentian Diagnostics ASA share price forecast for 2025?
The analyst consensus target price for shares in Gentian Diagnostics ASA is NOK67.00. That is 34% above the last closing price of NOK50.00.
Analysts covering Gentian Diagnostics ASA currently have a consensus Earnings Per Share (EPS) forecast of NOK1.78 for the next financial year.
Find out moreWhat is the trend in the Gentian Diagnostics ASA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Gentian Diagnostics ASA. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +17.7%.
As of the last closing price of NOK50.00, shares in Gentian Diagnostics ASA were trading +7.28% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Gentian Diagnostics ASA PE Ratio?
The Gentian Diagnostics ASA PE ratio based on its reported earnings over the past 12 months is 24.69. The shares last closed at NOK50.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Gentian Diagnostics ASA?
We do not have data on Gentian Diagnostics ASA's directors